Approaches to Achieving Sub-cellular Targeting of Bioactives Using Pharmaceutical Nanocarriers - Intracellular Delivery: Fundamentals and Applications - page 68

trafficking. There are several unanswered questions. For example, do all nanocarriers
remain intact upon cell entry and subsequent disposition? Are there differences in
the disposition of vesicles in comparison to solid particles? What is the true influ-
ence of size on the intracellular disposition of various nanocarriers? Most important
is however the question of the mechanism by which the nanocarrier is able to
achieve selective uptake and delivery into the sub-cellular compartment. Despite
several reports of altered or improved sub-cellular accumulation associated with an
improvement in activity, it is still unclear how exactly this happens. It will take
much active research to answer these and other questions before sub-cellular
targeted nanocarrier-based therapies become commonplace.
References
Akita, H., et al., Multi-layered nanoparticles for penetrating the endosome and nuclear membrane
via a step-wise membrane fusion process. Biomaterials, 2009. 30 (15): p. 2940-9.
Allen, T.D., et al., The nuclear pore complex: mediator of translocation between nucleus and
cytoplasm. J Cell Sci, 2000. 113 (Pt 10) : p. 1651-9.
Bae, Y., et al., Preparation and biological characterization of polymeric micelle drug carriers
with intracellular pH-triggered drug release property: tumor permeability, controlled subcel-
lular drug distribution, and enhanced in vivo antitumor efficacy. Bioconjug Chem, 2005.
16 (1): p. 122-30.
Bareford, L.M. and P.W. Swaan, Endocytic mechanisms for targeted drug delivery. Adv Drug
Deliv Rev, 2007. 59 (8): p. 748-58.
Boddapati, S.V., et al., Mitochondriotropic liposomes. J Liposome Res, 2005. 15 (1-2): p. 49-58.
Boddapati, S.V., et al., Organelle-targeted nanocarriers: specific delivery of liposomal cer-
amide to mitochondria enhances its cytotoxicity in vitro and in vivo. Nano Lett, 2008. 8 (8):
p. 2559-63.
Boussif, O., et al., A versatile vector for gene and oligonucleotide transfer into cells in culture and
in vivo: polyethylenimine. Proc Natl Acad Sci U S A, 1995. 92 (16): p. 7297-301.
Breunig, M., S. Bauer, and A. Goepferich, Polymers and nanoparticles: intelligent tools for intra-
cellular targeting? Eur J Pharm Biopharm, 2008. 68 (1): p. 112-28.
Calzolari, A., et al., Transferrin receptor 2 is frequently expressed in human cancer cell lines.
Blood Cells Mol Dis, 2007. 39 (1): p. 82-91.
Castino, R., M. Demoz, and C. Isidoro, Destination 'lysosome': a target organelle for tumour cell
killing? J Mol Recognit, 2003. 16 (5): p. 337-48.
Cervetti, G., et al., Efficacy and toxicity of liposomal daunorubicin included in PVABEC regimen
for aggressive NHL of the elderly. Leuk Lymphoma, 2003. 44 (3): p. 465-9.
Costin, G.E., et al., pH-sensitive liposomes are efficient carriers for endoplasmic reticulum-targeted
drugs in mouse melanoma cells. Biochem Biophys Res Commun, 2002. 293 (3): p. 918-23.
Demeneix, B. and J.P. Behr, Polyethylenimine (PEI). Adv Genet, 2005. 53 : p. 217-30.
D'Souza, G.G., et al., DQAsome-mediated delivery of plasmid DNA toward mitochondria in living
cells. J Control Release, 2003. 92 (1-2): p. 189-97.
D'Souza, G.G., S.V. Boddapati, and V. Weissig, Mitochondrial leader sequence--plasmid DNA
conjugates delivered into mammalian cells by DQAsomes co-localize with mitochondria.
Mitochondrion, 2005. 5 (5): p. 352-8.
D'Souza, G.G., et al., Nanocarrier-assisted sub-cellular targeting to the site of mitochondria
improves the pro-apoptotic activity of paclitaxel. J Drug Target, 2008. 16 (7): p. 578-85.
Dufes, C., et al., Anticancer drug delivery with transferrin targeted polymeric chitosan vesicles.
Pharm Res, 2004. 21 (1): p. 101-7.